DALLAS, May 17, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that several of the Company’s officers
DALLAS, May 15, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced results from its 2024 Annual Meeting of
Q1 Overview Research & Development Revenue of $6.3 Million Improved Capital Structure Reflected in Cash of $10.2 Million DeepView AI ® -Burn Devices Deployed in UK; Expect Commercial Revenue in 2H 2024 Additional Regulatory Submissions in US and UK for DeepView™ System Expected in 2024 and 2025
DALLAS, May 02, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that management is scheduled to present
DALLAS, April 30, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that the company received the
DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced that it will report financial results
Spangenberg brings significant IP monetization experience and the potential to unlock additional value for Spectral AI shareholders DALLAS, April 24, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on
Experienced Burn Industry Executive Champions Pivot to Commercialization DALLAS, April 01, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment
2023 Research & Development Revenue of $18.1 Million Expected to Increase to $28.0 Million in 2024 Commercialization Underway with Revenue Expected in 2H 2024 for DeepView AI ® -Burn Indication in the UK On Track for Additional Regulatory Submissions in US and UK for DeepView™ System Burn and
Issuance of Convertible Instrument Balances Certainty, Timing, and Execution Capital Supports Strategic Imperatives and Commercialization Initiatives DALLAS, March 20, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”) , an artificial intelligence (AI)
